For lab research use only, not for human therapeutic use.
At Creative Biolabs, we enhance your research and data relevancy by acquiring and reprogramming induced pluripotent stem cells (iPSC) from a specific patient clinical profile. Our pipeline is designed to meet the clients’ project and specific assay requirements for cellular characteristics and functions.
Direct reprogramming of somatic cells into induced pluripotent stem (iPS) cells is a valuable method to produce patient-specific stem cells of any lineage without the use of embryonic materials. Various new strategies have been developed to improve the reprogramming technologies since the first report of iPS cells generation from murine fibroblasts using retroviral transduction of a defined set of transcription factors. Methods of factor reprogramming fall into two broad categories: chemical and transgene reprogramming. It has been reported that many small molecules promote reprogramming when used with classical reprogramming factors. Creative Biolabs has developed streamed-line protocols for efficient iPSC generation with viral vectors, DNA (plasmid), RNA and recombinant proteins. Each of our services will be provided with a comprehensive report suitable for publications.
The primary factors to consider when deciding on a reprogramming method to generate iPSCs are what cell is being reprogrammed, the ability of the reprogramming method to adequately reprogram this cell type, as well as whether the presence of integrated sequences in the iPSCs will hinder downstream application.
Fig.1 The current reprogramming strategies used to induce pluripotent stem cells from adult somatic cells. (Lai, 2011)
Creative Biolabs is a worldwide leader in cell culture, including inducible cell line generation, and induced pluripotent stem cells culture. Creative Biolabs provides IPSC maintenance services and large-scale pluripotent cell production in both 2D and 3D formats. Based on our expertise in cell and stem cell biology, scientists at Creative Biolabs have developed unique media that are indispensable for iPSC research. Moreover, special products associated with advanced cell culture have been successfully established to help solve the problem involved in daily culture work, including mycoplasma detection kits and BacAway contamination control agents.
Technological advances have made it increasingly easy to generate iPSC, but the characteristics of the various lines produced may vary depending on their source, derivation, passage number and culture conditions. To confirm the pluripotency, quality, identity, and safety of the pluripotent cell lines as they are derived and maintained, it is essential to perform a set of characterization analyses. Our assay development is led by scientists with extensive experience in pluripotent characterization. Working seamlessly with our iPSC generation, genome editing and cell differentiation resources, our assay development teams provides a fully integrated service to customers wishing to become the leaders of the iPSC-based drug discovery field.
Creative Biolabs provides custom genome editing services in human cells, including cell lines and patient-derived cells. Although genome editing is not available for many somatic cell types, our iPSC-based services can be flexibly tailored to your needs through genome editing.
Creative Biolabs has extensive expertise in iPSC differentiation and can provide the most flexible, adaptable, and customizable solutions for your project. Different cell types are available, such as hepatocytes, cardiomyocytes, and neural cells. Other services include qRT-PCR of pluripotency genes, karyotyping for assessing genomic stability, and tri-lineage differentiation for assessing pluripotency in vitro.
Fig.2 Schematic overview of approaches to 1) differentiate smooth muscle cells (SMC) from induced pluripotent stem cells (iPSC), 2) use SMC to model vascular diseases, and 3) modulate cellular function through different microenvironmental cues. (Ji, 2017)
With world-class expertise in the derivation, bioprocess scale-up, and differentiation of induced human pluripotent stem cells, our services team can finish the iPSC projects and provide pluripotent stem cells to you in as little as 16-24 weeks. The actual timelines will vary depending on the type of cell provided, the choice of iPSC technology and the choice of other alternative characterization services.
The potentials of iPS cell technology in cell-based therapies, reproductive medicine, and biomedical research are too great to ignore. Proper reprogramming strategies are critical to creating patient- and disease-specific stem cells which can be used in regenerative medicine. Creative Biolabs’ stem cell program offers world-class expertise in the generation, bioprocess scale-up, and differentiation of iPSCs and uses this to provide solutions for your iPSC needs. Contact us today to discuss your iPSC project with a technical specialist.
Contact us for more informationGet free consultations